Compare VYGR & KRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | KRMD |
|---|---|---|
| Founded | 2013 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.0M | 195.7M |
| IPO Year | 2015 | 2019 |
| Metric | VYGR | KRMD |
|---|---|---|
| Price | $3.95 | $4.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $21.00 | $6.50 |
| AVG Volume (30 Days) | ★ 624.9K | 145.2K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ N/A |
| Revenue | $10,135,000.00 | ★ $41,127,366.00 |
| Revenue This Year | $34.04 | $20.32 |
| Revenue Next Year | $7.92 | $17.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $2.65 | $2.08 |
| 52 Week High | $5.55 | $6.61 |
| Indicator | VYGR | KRMD |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 45.73 |
| Support Level | $3.72 | $4.08 |
| Resistance Level | $4.30 | $4.34 |
| Average True Range (ATR) | 0.22 | 0.20 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 55.45 | 63.83 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.